drugset / Trial / NCT02235272
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
Timeline
- Start
- 2014-09
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BRIMAPITIDE | Protein / enzyme biologic | 900 ug | Other |